Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT05929222

Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

Conditions: Follicular Lymphoma

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: PHASE3

Enrollment: 190

Sponsor: Fondazione Italiana Linfomi - ETS

Location: Nuovo Ospedale Civile di Sassuolo - Day Hospital Oncologico Sassuolo Modena (MO)

Summary

Prospective, multicenter, open label, phase III randomized clinical trial in previously untreated Follicular Lymphoma in early stage. Patients will be randomized to receive Radiotherapy or Radiotherapy plus Obinutuzumab.

Eligibility Criteria

Inclusion Criteria: 1. Histological documented diagnosis of Follicular Lymphoma grade I-IIIA as defined in the 2017 edition of World Health Organization (WHO) 2. Ann Arbor Stage IA or IIA (includible in one radiation field), or IE, non-bulky (\

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05929222). StuddyBuddy aggregates publicly available trial information.